Studies of variations of subcutaneously infused desferrioxamine and iron movements in thalassaemia children

[1]  E. Chew,et al.  Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. , 1986, The New England journal of medicine.

[2]  J. Ducobu,et al.  OCULAR TOXICITY OF DESFERRIOXAMINE , 1985, The Lancet.

[3]  F. Mandelli,et al.  A study of the mechanisms and sites of action of desferrioxamine in thalassaemia major. , 1984, Acta haematologica.

[4]  B. Modell,et al.  The Clinical Approach to Thalassaemia , 1984 .

[5]  C. Borgna-Pignatti,et al.  VISUAL LOSS IN PATIENT ON HIGH-DOSE SUBCUTANEOUS DESFERRIOXAMINE , 1984, The Lancet.

[6]  K. Ang,et al.  DESFERRIOXAMINE, OCULAR TOXICITY, AND TRACE METALS , 1983, The Lancet.

[7]  G. Arden,et al.  OCULAR TOXICITY OF HIGH-DOSE INTRAVENOUS DESFERRIOXAMINE , 1983, The Lancet.

[8]  M. Pippard,et al.  Ferrioxamine excretion in iron-loaded man. , 1982, Blood.

[9]  R. Peto,et al.  Survival and desferrioxamine in thalassaemia major. , 1982, British medical journal.

[10]  G. Masera,et al.  Haemoglobin levels and blood requirement in thalassaemia. , 1982, Archives of disease in childhood.

[11]  K. Betke,et al.  Intravenous and subcutaneous desferrioxamine therapy in children with severe iron overload , 1981, European Journal of Pediatrics.

[12]  A. Cohen,et al.  DECREASING IRON STORES DURING INTENSIVE CHELATION THERAPY * , 1980 .

[13]  A. Jacobs,et al.  Studies in Desferrioxamine and Ferrioxamine Metabolism in Normal and Iron‐Loaded Subjects , 1979, British journal of haematology.

[14]  D. Weatherall,et al.  PREVENTION OF IRON LOADING IN TRANSFUSION-DEPENDENT THALASSÆMIA , 1978, The Lancet.

[15]  J. Graziano,et al.  Chelation therapy in beta-thalassemia major. I. Intravenous and subcutaneous deferoxamine. , 1978, The Journal of pediatrics.

[16]  W. Anderson,et al.  Continuous Subcutaneous Administration of Deferoxamine in Patients with Iron Overload , 1977 .

[17]  P. Houzé,et al.  Quantification of desferrioxamine in blood plasma by inductively coupled plasma atomic emission spectrometry. , 1987, Clinical chemistry.

[18]  S. De Virgiliis,et al.  Effect of subcutaneous desferrioxamine on iron balance in young thalassemia major patients. , 1983, The American journal of pediatric hematology/oncology.

[19]  S. De Virgiliis,et al.  Auditory involvement in thalassemia major. , 1979, Acta haematologica.